BR
BRIBF.US Brii Biosciences Limited
- Market cap
- USD 93.7M
- P/E
- -
- P/B
- 0.28x
- ROE
- -17.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BRIBF.US undervalued?
Graham numberThe Graham number of Brii Biosciences Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Brii Biosciences Limited fundamental analysis
No fundamental analysis for Brii Biosciences Limited yet.
Brii Biosciences Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for f…
Full company profileBrii Biosciences Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Brii Biosciences Limited annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 20.2M | 82.2M | 92.5M | 51.6M | 617K | 49.9M | 18.1M | - |
| Gross Profit | 20.2M | 82.2M | 92.5M | 51.6M | 617K | 49.9M | - | -15.3M |
| Operating Income | -525M | -897M | -610M | -514M | -544M | -404M | -296M | -595M |
| EBITDA | -119M | -883M | -593M | -497M | -168M | -395M | -290M | -580M |
| Net Income | -517M | -1.21B | -4.12B | -484M | -175M | -508M | -217M | -397M |
| EPS | -0.73 | -1.71 | -9.38 | -0.67 | -0.24 | -0.70 | -0.30 | -0.54 |
| Balance Sheet | ||||||||
| Total Assets | 1.04B | 1.27B | 3.61B | 3.39B | 3.20B | 2.71B | 2.36B | 2.20B |
| Total Liabilities | 1.65B | 3.01B | 300M | 234M | 126M | 101M | 36.2M | 36.4M |
| Shareholders' Equity | -613M | -1.74B | 3.34B | 3.19B | 3.12B | 2.66B | 2.38B | 2.22B |
| Cash & Short-term Investments | 880M | 1.05B | 3.35B | 3.00B | 2.66B | 2.32B | 1.94B | 1.77B |
| Total Debt | 35.1M | 28.3M | 21.6M | 12.7M | 3.16M | 28.0M | 8.93M | 6.18M |
| Cash Flow | ||||||||
| Operating Cash Flow | -67.3M | -404M | -879M | -496M | -594M | -373M | -287M | -527M |
| Capital Expenditure | 24.1M | 1.03M | 1.03M | 139M | 49.6M | 3.23M | 1.87M | 38.4M |
| Free Cash Flow | -91.4M | -404M | -880M | -636M | -644M | -376M | -288M | -566M |
| Ratios | ||||||||
| ROE | - | - | -123.3% | -15.2% | -5.6% | -19.1% | -9.1% | -17.9% |
| ROA | -49.7% | -95.1% | -114.1% | -14.3% | -5.5% | -18.8% | -9.2% | -18.0% |
| Net Profit Margin | -2,559.1% | -1,467.2% | -4,452.3% | -938.1% | -28,335.3% | -1,017.6% | -1,196.6% | - |
| Debt to Equity | - | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Brii Biosciences Limited dividends
Brii Biosciences Limited has not paid dividends in the last 7 fiscal years.
Who owns Brii Biosciences Limited
- Insiders 5.13%
- Institutions 12.77%
- Public & others 82.10%
- Shares outstanding 721M
- Free float 594M
Brii Biosciences Limited company profile
- Company name
- Brii Biosciences Limited
- Ticker
- BRIBF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 80
- Fiscal year end
- December
- Address
- Building 7, International Science Park, Beijing, China, 100192
- Website
- briibio.com
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Brii Biosciences Limited management
10- Dr. Zhi Hong Ph.D.Co-founder, Executive Chairman of the Board & CEO · born 1963
- Dr. Ankang Li C.F.A., J.D., Ph.D.COO, Joint Secretary & Executive Director · born 1979
- Dr. Eleanor de Groot Ph.D.Chief Technology Officer · born 1969
- Dr. Brian Alvin Johns Ph.D.Chief Scientific Officer · born 1971
- Sarah QiuAssociate Director of Investor Relations
- Ms. Karen Del Barrio NeuendorffChief People Officer & Head of Human Resources · born 1976
- Dr. Qing Zhu Ph.D.Head of Pre-clinical Sciences and Translational Research · born 1968
- Dr. David Margolis M.D., M.P.H.Chief Medical Officer · born 1975
- Mr. Haifeng CaoHead of China Development · born 1973
- Ms. Wing Tsz Ho CGP, FCIS, FCS, M.B.A., P.E.Joint Company Secretary · born 1970